Press Releases

Press Releases

or

July 3, 2018
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) CAMBRIDGE, Mass., and BEIJING, China, July 03, 2018 (GLOBE NEWSWIRE) --  BeiGene, Ltd.  (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and
June 5, 2018
CAMBRIDGE, Mass. and BEIJING, China , June 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the
May 15, 2018
CAMBRIDGE, Mass. and BEIJING, China , May 15, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the
May 9, 2018
CAMBRIDGE, Mass. and BEIJING, China , May 09, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today reported recent